- Full Time Employees
- 96
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seongnam-si South Korea
- IPO Date
- Dec 26, 2018
- Business
- Genome & Company is a clinical-stage biotechnology company that discovers, develops, and commercializes antibody-drug conjugates (ADCs), novel target immuno-oncology biologics, microbiome-based therapeutics, and microbiome-derived consumer healthcare products, while providing specialized contract development and manufacturing organization (CDMO) services. Founded in 2015 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates research, clinical, and manufacturing facilities across South Korea and the United States, targeting global biopharmaceutical markets and consumer healthcare sectors. Genome & Company utilizes its proprietary GNOCLE drug discovery platform to translate clinical data into novel therapeutic targets, operating across four primary business segments: Antibody-Drug Conjugates and Novel Biologics, encompassing GENA-111, an ADC candidate targeting CD239 for solid tumors, and GENA-104 (EP0089), a first-in-class monoclonal antibody targeting contactin-4 (CNTN4) for refractory oncology indications; Microbiome Therapeutics, comprising GEN-001, an oral microbiome therapeutic candidate developed for immuno-oncology combination treatments including PD-L1-positive gastric cancer, and SB-121, a bacterial formulation for central nervous system disorders such as autism spectrum disorder developed via subsidiary Scioto Biosciences; Contract Development and Manufacturing Organization (CDMO) Services, offering end-to-end process development, analytical testing, and cGMP manufacturing for live biotherapeutic products (LBPs) and microbial therapeutics through U.S.-based operating subsidiaries List Biological Laboratories, Inc. and List Biotherapeutics, Inc.; and Consumer Healthcare and Cosmetics, marketing functional derma-cosmetic products formulated with patented microbiome ingredients under the proprietary commercial brand UIQ. In recent corporate developments, Genome & Company executed a strategic operational pivot to concentrate capital and clinical resources on its high-value ADC and novel antibody pipeline. In May 2024, the company entered into an exclusive global licensing agreement valued at up to 425.6 million USD (586 billion KRW) with Swiss biopharmaceutical firm Debiopharm to develop and commercialize GENA-111 (designated Debio 0633) utilizing Debiopharm Multilink technology. In February 2025, Genome & Company finalized an exclusive worldwide licensing and development agreement with UK-based Ellipses Pharma for the clinical advancement of GENA-104. Concurrently, the company completed Phase 2 combination trials for GEN-001 with avelumab in gastric cancer while deprioritizing new early-stage standalone microbiome programs to optimize R&D expenditure, and accelerated international distribution and retail expansion for its UIQ consumer brand across key Asian markets.